Since toxicity is one of the leading causes of drug failures, measuring preclinical toxicity is a critical drug development function. Accurate in vivo toxicity assays are essential to lowering attrition and increasing efficiency in drug development.
Bioo Scientific announced today the launch of their MaxDiscovery™ Toxicity Assay Kits. These kits monitor in vivo toxicity by measuring liver and heart function in serum samples. They provide simple, convenient, colorimetric determination of well-characterized functional markers of for liver and heart. They are ideal tools to monitor toxic effects caused by administration of siRNA, DNA plasmids, transfection agents or other therapeutic treatments during preclinical studies. The assays can be used in a range of mammals, including mice and rats, providing a powerful tool to assess and reduce the toxicity of drugs formulations and to improve drug delivery methods.
According to Dr Joe Krebs, Director of Protein Chemistry and Engineering at Bioo Scientific, “MaxDiscovery™ Toxicity kits are designed to provide researchers with rapid, cost-effective tools required to address the escalating challenges of drug development in today’s competitive landscape.” Assays are available for alanine transaminase, aspartate transminase, alkaline phosphatase, lactate dehydrogenase, cholesterol, and creatine kinase.
About Bioo Scientific
Bioo Scientific Corporation (www.biooscientific.com) is a global biotechnology tools company, headquartered in Austin, Texas. Bioo Scientific provides innovative products and services to academic researchers, pharmaceutical and biotechnology companies, molecular diagnostics laboratories, and customers who perform food and feed safety analysis.
